Physician profile
Scott Capustin
NPI 1770517211
$7,007.04
in general payments reported to CMS, 2019-2025
34 companies · $809 in 2025
The $809 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,242 · 2020: $925 · 2021: $900 · 2022: $1,208 · 2023: $996 · 2024: $926 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,731.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,328.28 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $1,126.54 | 2019-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $839.31 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $759.91 | 2019-2024 | Fasenra, Breztri, Symbicort |
| Grifols USA, LLC | $644.04 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $580.14 | 2019-2024 | |
| Amgen INC. | $252.27 | 2021-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $205.02 | 2019-2024 | Verquvo, Recarbrio, Zerbaxa |
| Actelion Pharmaceuticals US, INC. | $142.21 | 2019-2023 | Opsumit |
| Tetraphase Pharmaceuticals, INC. | $116.62 | 2020 | |
| Baxter Healthcare | $114.70 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $97.18 | 2024-2025 | Vest Therapy Und, (Ck7) Extended Holter |
| Verona Pharma, INC. | $71.80 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $71.10 | 2024-2025 | Glassia |
| Mylan Specialty L.P. | $68.53 | 2020-2024 | Yupelri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $64.64 | 2020-2022 | |
| Inspire Medical Systems, INC. | $50.21 | 2024-2025 | Inspire |
| Advanced Respiratory, INC | $45.28 | 2019 | |
| Insmed, INC. | $38.35 | 2025 | Brinsupri, Arikayce |
| Jazz Pharmaceuticals INC. | $37.86 | 2019 | |
| Inogen, INC. | $37.48 | 2023 | Inogen At Home Stationary Concentrator, Inogen One G5 Oxygen Concentrator - Bluetooth |
| Kowa Pharmaceuticals America, INC. | $37.41 | 2019-2020 | |
| Resmed Corp | $35.87 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $33.65 | 2021 | |
| Viatris Specialty LLC | $27.18 | 2025 | Yupelri |
| Genentech USA, INC. | $26.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.91 | 2024 | |
| Sunovion Pharmaceuticals INC. | $24.84 | 2019 | |
| Lundbeck LLC | $21.71 | 2024 | Rexulti |
| Dexcom, INC. | $18.03 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $17.68 | 2025 | |
| Esperion Therapeutics, INC. | $17.10 | 2022 | |
| Pfizer INC. | $15.75 | 2020 | |
| Olympus America INC. | $14.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Capustin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.